Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 2022

View Archived Issues

New xenograft model of sporadic inclusion body myositis shows no role of T-cell depletion

Novel mutations in the FGG gene tied to thrombosis and dysfibrinogenemia

ETV6 and FYB1 rare genetic mutations tied to inherited thrombocytopenia

Disruption of tumor N-glycosylation improves the efficacy of CAR T-cell therapy in solid carcinomas

A mitochondrial genetic signature characterizes the most aggressive liver cancers in mice and humans

New kinetic model for a minimal cell helps to quantitatively understand the principles of life

Drug-free nanoparticle scavenges cell-free DNA and ROS to treat inflammatory bowel disease

Tactogen patents 5-HT1B receptor agonists and MAO-A inhibitors

Selenium mediates neurogenesis after hippocampal injury

Aligos Therapeutics discloses new THR agonists

VelosBio identifies new anti-ROR1 ADCs

Klotho Therapeutics synthesizes novel compounds for hypertension

Bristol Myers Squibb presents new FPR agonists

Fibrinogen as marker of joint health in patients with severe hemophilia

eTheRNA and Merck KGaA sign research agreement to assess mRNA technology for therapeutic vaccination

Parkinson's UK and Domainex collaborate to target neuroinflammation to slow Parkinson's disease

Mindset to initiate proof-of-concept preclinical studies on Family 3 compounds for cognitive benefit

Ascletis reports preclinical data on ASC-10 and ASC-10-A against SARS-CoV-2 variants

Dyve and Moffitt collaborate to study buffering agent for transdermal delivery in cancer models

LinKinVax signs licensing agreement with Inserm for vaccine platform

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...